Gamida Cell

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Gamida Cell sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Gamida Cell: 8 sponsored US clinical trials, none currently recruiting.

Gamida Cell sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematological Malignancies, with 2 trials.

Upper-quartile sponsor footprint

Gamida Cell sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

TERMINATED Phase 1

Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

NCT05296525
COMPLETED Phase 3

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

NCT04260698
COMPLETED Phase 3

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

NCT02730299
TERMINATED Phase 1

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

NCT02504619
COMPLETED

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

NCT02039557
COMPLETED Phase 1

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

NCT01816230
COMPLETED Phase 1

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

NCT01590628
COMPLETED Phase 1

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

NCT01221857

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 3 2

Therapeutic Areas

Hematological Malignancies 2
Myelodysplastic Syndrome (MDS) 1
Acute Myeloid Leukemia (AML) 1
Acute Lymphoblastic Leukemia (ALL) 1

How the Gamida Cell early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 6 completed (75%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Hematological Malignancies (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Gamida Cell: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Gamida Cell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Gamida CellAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Gamida Cell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gamida Cell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gamida Cell page

8 registered trials is a research-attention snapshot, not an endorsement of Gamida Cell or any single study.

  • None of Gamida Cell's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hematological Malignancies is the condition Gamida Cell studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematological Malignancies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gamida Cell pipeline card: 8 registered trials from official public datasets.Report a data error.